WebDoctor Encyclopedia

Cutaneous lymphomas Lymphomas

Intravascular large B-cell lymphoma (IVLBCL)

Intravascular large B-cell lymphoma (IVLBCL) is an uncommon, fast-moving lymphoma that grows inside small blood vessels rather than forming lumps. It causes fever, confusion and skin changes in older adults, is diagnosed by skin and marrow biopsy and treated with R-CHOP.

Medically reviewed Last reviewed October 19, 2026

What is intravascular large B-cell lymphoma?

Intravascular large B-cell lymphoma (IVLBCL) is an uncommon, fast-moving form of non-Hodgkin lymphoma. What makes it unusual is where the cancer cells live: instead of forming lumps in lymph nodes, the lymphoma cells grow inside the smallest blood vessels, such as capillaries, throughout the body.

Because there is usually no visible tumour or enlarged lymph node, IVLBCL is one of the most difficult cancers to diagnose. It often shows up as unexplained fever, confusion or stroke-like episodes, skin changes or abnormal blood tests, and it has been called “a chameleon with many masks” (Ponzoni, Campo and Nakamura, 2018).

The disease mainly affects older adults, with an average age around 70. Without treatment it progresses quickly, and in the past many cases were only discovered after death. Today, with earlier diagnosis using skin and bone marrow biopsies and treatment with R-CHOP chemotherapy combined with treatment aimed at the brain, most people respond well and many remain in remission for years (Shimada et al., 2025).

1. Key facts at a glance

Feature Details
Type of cancer Aggressive B-cell non-Hodgkin lymphoma inside small blood vessels
How common Rare; well under 1 case per million people per year in most countries
Typical age Older adults; median about 70
Sex Men and women affected about equally; the skin-only form is more common in women
Common sites Brain, skin, bone marrow, lungs, kidneys, adrenal glands, liver and spleen
Main clues Fever, confusion, skin patches, low blood counts, very high LDH
Key test Random deep skin biopsy and bone marrow biopsy
Main treatment R-CHOP plus high-dose methotrexate and spinal fluid chemotherapy
Outlook Much improved; about 3 in 4 alive at 5 years in a recent trial

2. Types of IVLBCL

Type Main features Notes
Classic type Brain and skin symptoms, fever More often described in Western countries
Haemophagocytic syndrome-associated type Fever, low blood counts, big liver and spleen, bone marrow involvement More often described in East Asia; formerly called the “Asian variant”
Cutaneous (skin-only) type Disease limited to the skin Mainly women; better outlook (Breakell et al., 2022)

3. Causes and risk factors

The cause of IVLBCL is not known. It is not infectious and is not inherited.

Factor Notes
Older age Most patients are over 60
Weakened immune system Occasionally reported, but most patients have no immune problem
Gene changes in the tumour MYD88 and CD79B mutations are common, similar to some other extranodal lymphomas

Why do the cells stay inside vessels?

Researchers believe the lymphoma cells lack certain “homing” molecules that normally let white blood cells leave the bloodstream and enter tissues. As a result, they become trapped inside small vessels, where they block blood flow and cause damage to the organs supplied (Shimada and Kiyoi, 2021).

4. How does it look

On the skin

About 1 in 4 to 1 in 3 people have skin involvement, though the skin can be affected even when it looks normal.

Feature Description
Patches Red, purple or bruise-like areas
Plaques and lumps Firm, slightly raised areas, sometimes painful
Blood vessels Visible small vessels (telangiectasia)
Swelling Puffy, firm skin, often on the thighs or tummy
Common sites Thighs, abdomen, breasts, arms

On scans

Standard CT scans often look normal or show only subtle changes. Clues may include:

Scan Possible findings
Brain MRI Small areas of damage resembling strokes, or patchy white-matter changes
CT chest Hazy shadows in the lungs
PET-CT Increased activity in the bone marrow, spleen, adrenal glands, lungs or kidneys
Ultrasound Enlarged liver or spleen

Under the microscope

Feature Description
Location Large lymphoma cells filling the inside of small vessels, with little or no tumour outside them
Cells Large B cells with prominent nucleoli and many mitoses
Markers CD20 and CD79a positive; often MUM1 positive and CD10 negative
Highlight stain CD34 or other vessel stains show the cells lie within vessel walls
Skin biopsy Cells often found in the small vessels of the fat layer

5. Symptoms

Symptoms depend on which organs’ small vessels are blocked. They are often vague and varied, which is why the diagnosis is frequently delayed.

General symptoms

  • Fever without an obvious cause, often lasting weeks
  • Night sweats and weight loss
  • Severe tiredness
  • Loss of appetite

Symptoms by organ

Organ Possible symptoms
Brain Confusion, memory loss, rapidly worsening dementia, stroke-like weakness, seizures, unsteadiness
Spinal cord and nerves Leg weakness, numbness, bladder problems
Skin Painful red or purple patches and firm swelling
Lungs Breathlessness, low oxygen levels, cough
Bone marrow Anaemia, bleeding, infections
Adrenal glands Low blood pressure, weakness, salt imbalance
Kidneys Protein in the urine, kidney failure
Liver and spleen Abdominal swelling, jaundice

Blood test clues

Test Typical finding
LDH Very high
Soluble IL-2 receptor Very high
Blood counts Anaemia, low platelets
Ferritin High, especially with haemophagocytic syndrome
Inflammation markers Raised CRP and ESR

When to seek medical advice

See a doctor about fever lasting more than a week or two without an obvious cause, unexplained weight loss, or new memory problems or confusion. Seek emergency care for sudden weakness, difficulty speaking, a seizure or severe breathlessness.

6. Diagnosis

IVLBCL is often considered only after many other tests have been normal. Doctors suspect it in people with unexplained fever, neurological symptoms and very high LDH.

Test Purpose
Random skin biopsy Several deep biopsies of normal-looking skin, including fat, often from the thighs and abdomen; a key test
Biopsy of abnormal skin If patches or lumps are present
Bone marrow biopsy Frequently shows lymphoma cells
PET-CT Shows areas of hidden disease and guides biopsy
Brain MRI and lumbar puncture Checks for brain and spinal fluid involvement
Biopsy of other organs Such as the adrenal gland, lung or kidney when abnormal on scans
Blood tests LDH, sIL-2R, ferritin, kidney and liver function

Random skin biopsy explained

Step What happens
1. Choosing sites Usually 3 or more areas of normal-looking skin with fatty tissue, such as the thighs and lower abdomen
2. Local anaesthetic The skin is numbed with a small injection
3. Biopsy A small, deep piece of skin and fat is removed, usually with a punch or small incision
4. Closing One or two stitches; a dressing is applied
5. Results Pathologists look for lymphoma cells inside small vessels, usually within a few days

The procedure is quick and done at the bedside or in clinic, and it can make the diagnosis without the need for more invasive surgery.

Conditions that can look similar

Condition Notes
Infections Such as tuberculosis or endocarditis, causing fever of unknown origin
Vasculitis Inflammation of blood vessels, which can also cause brain and skin problems
Strokes from other causes Similar MRI appearance
Other causes of haemophagocytic syndrome Including other lymphomas and infections

7. Treatment

Treatment is given by a lymphoma team and should start as soon as possible, because the disease progresses quickly.

First treatment

Treatment Notes
R-CHOP Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone, usually 6 cycles
High-dose methotrexate Given between or after R-CHOP cycles to protect the brain
Intrathecal chemotherapy Drugs injected into the spinal fluid
Supportive care Transfusions, antibiotics, treatment of low blood pressure or adrenal failure

In the Japanese PRIMEUR-IVL trial, 37 patients without brain involvement at diagnosis received this combined approach. After about 7 years of follow-up, 68% remained free of progression and 78% were alive at 5 years, and the lymphoma rarely spread to the brain (Shimada et al., 2025).

If the brain is involved at diagnosis

Treatment follows approaches used for primary brain lymphoma, with higher doses of drugs that reach the brain, such as methotrexate and cytarabine, sometimes followed by high-dose chemotherapy with stem cell rescue in fit patients.

Relapsed disease

Option Notes
Second-line chemotherapy Platinum or other combinations
Stem cell transplant For fit patients who respond
CAR T-cell therapy and bispecific antibodies Used for relapsed large B-cell lymphomas and increasingly considered in IVLBCL
BTK inhibitors Such as ibrutinib, being studied, especially with brain involvement
Clinical trials Encouraged where available

Side effects

Treatment Possible side effects
R-CHOP Hair loss, sickness, infections, tingling in hands and feet, constipation, tiredness
High-dose methotrexate Kidney and liver effects, mouth sores; needs hospital stay and monitoring
Intrathecal chemotherapy Headache, back pain
Steroids High blood sugar, mood changes, sleep problems

What treatment involves day to day

Part of treatment What to expect
R-CHOP Day-unit treatment every 3 weeks for about 4-5 months
High-dose methotrexate Hospital stay of 2-4 days per course
Lumbar punctures Short procedures for spinal fluid chemotherapy
Blood tests Before each cycle and in between

8. Outlook (prognosis)

Situation Approximate outlook
Before rituximab Poor; many patients died within a year
R-CHOP-based treatment Large improvement; most respond
R-CHOP plus CNS-directed treatment (PRIMEUR-IVL) About 78% alive and 68% progression-free at 5 years
Cutaneous type Usually better than other types
Brain involvement or haemophagocytic syndrome Generally more difficult to treat

Older age, poor fitness, brain involvement and delayed diagnosis are linked with a poorer outlook. Prompt diagnosis is the single most important step (Davis et al., 2022).

9. Follow-up

Follow-up Purpose
Clinic visits every 3 months for 2 years Check symptoms and examine the skin and nervous system
Blood tests LDH, sIL-2R and blood counts can signal relapse
PET-CT After treatment to confirm remission, and if relapse is suspected
Brain MRI If new neurological symptoms appear
Late effect monitoring Heart function after doxorubicin, nerve damage, second cancers

10. Living with intravascular large B-cell lymphoma

  • Report fevers immediately during chemotherapy, as infections can be serious
  • Ask about memory and rehabilitation support if the brain was affected
  • Keep active within your limits; gentle exercise such as walking helps fatigue
  • Ask for help at home from family, carers or community services during treatment
  • Keep a symptom diary to share at follow-up, including fevers, memory changes and skin patches
  • Seek support from lymphoma charities and patient groups

11. Frequently asked questions

Question Answer
Why was it so hard to diagnose? It does not form lumps and causes symptoms that look like many other illnesses
Why did I have biopsies of normal skin? Lymphoma cells are often hidden in skin vessels even when the skin looks normal
Is it curable? Many people achieve long-lasting remission with modern treatment
Will it affect my brain? It can; that is why treatment includes drugs aimed at the brain
Is it inherited? No
Is it related to other lymphomas? Yes, it is a type of large B-cell lymphoma, the most common lymphoma family

12. Questions to ask your care team

  • Which type of IVLBCL do I have?
  • Is my brain or spinal fluid involved?
  • What will my treatment plan involve, and how long will it last?
  • Will I need high-dose methotrexate or spinal fluid treatment?
  • What side effects should I report straight away?
  • What happens if the lymphoma comes back?

Resources

  1. Breakell, T. et al. (2022) ‘Intravascular large B-cell lymphoma: a review with a focus on the prognostic value of skin involvement’, Current Oncology, 29(5), pp. 2909-2919.
  2. Davis, J.W. et al. (2022) ‘Intravascular large B-cell lymphoma’, Archives of Pathology and Laboratory Medicine, 146(9), pp. 1160-1167.
  3. Ponzoni, M., Campo, E. and Nakamura, S. (2018) ‘Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks’, Blood, 132(15), pp. 1561-1567.
  4. Shimada, K. and Kiyoi, H. (2021) ‘Current progress and future perspectives of research on intravascular large B-cell lymphoma’, Cancer Science, 112(10), pp. 3953-3961.
  5. Shimada, K. et al. (2020) ‘Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial’, Lancet Oncology, 21(4), pp. 593-602.
  6. Shimada, K. et al. (2025) ‘Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial’, EClinicalMedicine, 80, 103078.
  7. National Cancer Institute (2026) Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/aggressive-b-cell-lymphoma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.